Paltusotine and Encorafenib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Encorafenib
Paltusotine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced paltusotine exposure and reduced efficacy of paltusotine
Interaction Deep Dive
Concomitant use of paltusotine with strong CYP3A4 inducers may reduce paltusotine exposure and may affect therapeutic response, thus may require an increased dosage of paltusotine. Do not to exceed three-fold the dose prior to concomitant use or 120 mg daily, whichever is less. In a drug interaction study, coadministration of paltusotine and carBAMazepine (strong CYP3A4 inducer) reduced Cmax and AUC by approximately 44% and 70%, respectively1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of paltusotine
Literature reports
1 report — tap to read
a) In a drug interaction study, coadministration of paltusotine and carBAMazepine (strong CYP3A4 inducer) reduced Cmax and AUC by approximately 44% and 70%, respectively 1.
Common questions
Can I take Paltusotine and Encorafenib together?
Reduced paltusotine exposure and reduced efficacy of paltusotine Always confirm with your pharmacist or prescriber before making any change.
How serious is the Paltusotine and Encorafenib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Paltusotine or Encorafenib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: PALSONIFY™ oral tablets, paltusotine oral tablets. Crinetics Pharmaceuticals, Inc (per FDA), San Diego, CA, 2025. DailyMed
Keep reading about Encorafenib
Keep reading about Paltusotine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist